New Approaches and Repurposed Antiviral Drugs for the Treatment of the SARS-CoV-2 Infection
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that causes coronavirus disease 2019 (COVID-19). The outbreak of this coronavirus was first identified in Wuhan (Hubei, China) in December 2019, and it was declared as pandemic by the World Health Organization (WHO) in March 2...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-05-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/14/6/503 |
| _version_ | 1827691578609631232 |
|---|---|
| author | Luana Vittoria Bauso Chiara Imbesi Gasparo Irene Gabriella Calì Alessandra Bitto |
| author_facet | Luana Vittoria Bauso Chiara Imbesi Gasparo Irene Gabriella Calì Alessandra Bitto |
| author_sort | Luana Vittoria Bauso |
| collection | DOAJ |
| description | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that causes coronavirus disease 2019 (COVID-19). The outbreak of this coronavirus was first identified in Wuhan (Hubei, China) in December 2019, and it was declared as pandemic by the World Health Organization (WHO) in March 2020. Today, several vaccines against SARS-CoV-2 have been approved, and some neutralizing monoclonal antibodies are being tested as therapeutic approaches for COVID-19 but, one of the key questions is whether both vaccines and monoclonal antibodies could be effective against infections by new SARS-CoV-2 variants. Nevertheless, there are currently more than 1000 ongoing clinical trials focusing on the use and effectiveness of antiviral drugs as a possible therapeutic treatment. Among the classes of antiviral drugs are included 3CL protein inhibitors, RNA synthesis inhibitors and other small molecule drugs which target the ability of SARS-COV-2 to interact with host cells. Considering the need to find specific treatment to prevent the emergent outbreak, the aim of this review is to explain how some repurposed antiviral drugs, indicated for the treatment of other viral infections, could be potential candidates for the treatment of COVID-19. |
| first_indexed | 2024-03-10T11:04:35Z |
| format | Article |
| id | doaj.art-9806385753ad455795dee419dc4cbb5a |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-10T11:04:35Z |
| publishDate | 2021-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-9806385753ad455795dee419dc4cbb5a2023-11-21T21:15:25ZengMDPI AGPharmaceuticals1424-82472021-05-0114650310.3390/ph14060503New Approaches and Repurposed Antiviral Drugs for the Treatment of the SARS-CoV-2 InfectionLuana Vittoria Bauso0Chiara Imbesi1Gasparo Irene2Gabriella Calì3Alessandra Bitto4Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, ItalyDepartment of Clinical and Experimental Medicine, University of Messina, 98125 Messina, ItalyDepartment of Clinical and Experimental Medicine, University of Messina, 98125 Messina, ItalyDepartment of Clinical and Experimental Medicine, University of Messina, 98125 Messina, ItalyDepartment of Clinical and Experimental Medicine, University of Messina, 98125 Messina, ItalySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that causes coronavirus disease 2019 (COVID-19). The outbreak of this coronavirus was first identified in Wuhan (Hubei, China) in December 2019, and it was declared as pandemic by the World Health Organization (WHO) in March 2020. Today, several vaccines against SARS-CoV-2 have been approved, and some neutralizing monoclonal antibodies are being tested as therapeutic approaches for COVID-19 but, one of the key questions is whether both vaccines and monoclonal antibodies could be effective against infections by new SARS-CoV-2 variants. Nevertheless, there are currently more than 1000 ongoing clinical trials focusing on the use and effectiveness of antiviral drugs as a possible therapeutic treatment. Among the classes of antiviral drugs are included 3CL protein inhibitors, RNA synthesis inhibitors and other small molecule drugs which target the ability of SARS-COV-2 to interact with host cells. Considering the need to find specific treatment to prevent the emergent outbreak, the aim of this review is to explain how some repurposed antiviral drugs, indicated for the treatment of other viral infections, could be potential candidates for the treatment of COVID-19.https://www.mdpi.com/1424-8247/14/6/503SARS-CoV-2antiviralsCOVID-19vaccine |
| spellingShingle | Luana Vittoria Bauso Chiara Imbesi Gasparo Irene Gabriella Calì Alessandra Bitto New Approaches and Repurposed Antiviral Drugs for the Treatment of the SARS-CoV-2 Infection Pharmaceuticals SARS-CoV-2 antivirals COVID-19 vaccine |
| title | New Approaches and Repurposed Antiviral Drugs for the Treatment of the SARS-CoV-2 Infection |
| title_full | New Approaches and Repurposed Antiviral Drugs for the Treatment of the SARS-CoV-2 Infection |
| title_fullStr | New Approaches and Repurposed Antiviral Drugs for the Treatment of the SARS-CoV-2 Infection |
| title_full_unstemmed | New Approaches and Repurposed Antiviral Drugs for the Treatment of the SARS-CoV-2 Infection |
| title_short | New Approaches and Repurposed Antiviral Drugs for the Treatment of the SARS-CoV-2 Infection |
| title_sort | new approaches and repurposed antiviral drugs for the treatment of the sars cov 2 infection |
| topic | SARS-CoV-2 antivirals COVID-19 vaccine |
| url | https://www.mdpi.com/1424-8247/14/6/503 |
| work_keys_str_mv | AT luanavittoriabauso newapproachesandrepurposedantiviraldrugsforthetreatmentofthesarscov2infection AT chiaraimbesi newapproachesandrepurposedantiviraldrugsforthetreatmentofthesarscov2infection AT gasparoirene newapproachesandrepurposedantiviraldrugsforthetreatmentofthesarscov2infection AT gabriellacali newapproachesandrepurposedantiviraldrugsforthetreatmentofthesarscov2infection AT alessandrabitto newapproachesandrepurposedantiviraldrugsforthetreatmentofthesarscov2infection |